Public Employees Retirement System of Ohio Purchases Shares of 540,457 Kenvue Inc. $KVUE

Public Employees Retirement System of Ohio acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 540,457 shares of the company’s stock, valued at approximately $10,328,000.

Several other hedge funds also recently modified their holdings of the company. Elyxium Wealth LLC bought a new position in shares of Kenvue in the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new stake in Kenvue during the 2nd quarter worth approximately $26,000. MV Capital Management Inc. acquired a new stake in Kenvue during the 4th quarter valued at $28,000. CoreCap Advisors LLC increased its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares in the last quarter. Finally, Reflection Asset Management bought a new position in Kenvue in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on KVUE. UBS Group reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Stock Down 1.4%

NYSE:KVUE opened at $18.90 on Tuesday. The stock’s fifty day moving average price is $19.18 and its two-hundred day moving average price is $18.25. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $20.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The company has a market cap of $36.30 billion, a price-to-earnings ratio of 21.72, a P/E/G ratio of 1.37 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.29 earnings per share. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a $0.21 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.